Tiragolumab is a novel immune checkpoint inhibitor that binds to TIGIT, a protein receptor on immune cells, which suppresses ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia. Landiolol is a selective beta-1 adrenergic ...

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

There was an increase in quarterly prescription rates from 4.2% in July to September 2021 to 23.5% in July to September 2023. (HealthDay News) — From 2021 to 2023, there was an increase in ...

The projected costs increased by $2,005,000, $763,000, and $1,164,000 per quality-adjusted life-year gained for expanding HPV vaccination to all mid-adults, those with more lifetime partners, and ...

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

The researchers used the Baltimore Longitudinal Study of Aging, a prospective cohort study of community-dwelling older adults.

Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...